Final Phase II Data Evaluating REVLIMID® and Rituximab in Patients with ... Business Wire (press release) In the study, 59 patients received rituximab 375 mg/m 2 intravenously weekly for four weeks in cycle one, and then once every four weeks during cycles three to 12. Oral lenalidomide 10 mg/day was started on day nine of cycle one and then on a ... Celgene Unit Releases Final Phase 2 Data Evaluating REVLIMID and Rituximab (CELG) Final Phase II Data Evaluating REVLIMID and Rituximab in Patients with ... REVLIMID(R) Evaluated in Combination with Rituximab as a Potential Treatment ... |
